biological source
human lung
packaging
tube of 5 μg 96042332-DNA-5UG, pkg of vial of cells 96042332-1VL
growth mode
Aggregates in suspension
karyotype
Not specified
morphology
Not specified
products
Not specified
receptors
Not specified
technique(s)
cell culture | mammalian: suitable
relevant disease(s)
cancer
shipped in
dry ice
storage temp.
−196°C
Application
Analysis of acquired drug resistance, study of small cell lung carcinoma, MDR studies.
Biochem/physiol Actions
Human Caucasian small cell lung carcinoma
The drug-resistant cell line NCI-H69/LX20 has been derived by exposure of the parent line, H69 (ECACC Number 91091802) to doxorubicin, also known as adriamycin. These multi drug resistant (MDR) cells have been found to be recognised by various anti-P-glycoprotein antibodies.
Preparation Note
Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37°C. It is recommended to culture the cells without drug upon resuscitation until the first passage. Resuscitate into 9 ml of medium. Immediately after resuscitation perform a centrifugation ste
RPMI 1640 + 2mM Glutamine + 2μg/ml Doxorubicin + 10% Foetal Bovine Serum (FBS). ECACC has found that the following supplement will assist good growth of cells: sodium selenite 10nM, Insulin 250ng/ml, Transferrin 10ug/ml and sodium pyruvate 1mM.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.